Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series
Headache: The Journal of Head and Face Pain · 2026-09 · 66 (8) · 1916-1919
DOI: 10.1111/head.70152 ↗Kurz gefasst
Fallbericht in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 06.07.2026. Verfasst von Tulsi Shah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Capital Neurology and Sleep Medicine, McLean, Virginia, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Migraine Disorders, Receptors, Gastrointestinal Hormone, Tirzepatide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Obesity is a known comorbidity of migraine that can increase attack frequency and severity and lead to disease chronification. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and related medications have demonstrated benefits beyond glycemic control and weight management, with emerging evidence suggesting a potential role in pain modulation. Clinical observations have also suggested the role of GLP‐1 based therapies for the treatment of idiopathic intracranial hypertension, but their role in migraine has not been established. Case Series Here, we report two cases of patients with migraine who experienced a reduction in migraine headache frequency following initiation of tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist.
Discussion
These cases suggest that GLP‐1 receptor agonists and dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonists may have potential therapeutic relevance in migraine management. Notably, both patients experienced weight loss with treatment, which represents a significant confounding factor that limits conclusions about a direct migraine‐specific effect. These cases should be interpreted as preliminary observations. Future studies evaluating migraine outcomes in patients treated with these medications are needed to better understand the underlying mechanism and explore their potential role as novel therapeutic pathways for migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Capital Neurology and Sleep Medicine, McLean, Virginia, USA.
- Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.
- Virtua Neurosciences, Marlton, New Jersey, USA.
Zitieren
APA
Shah, T., Dougherty, C., Ailani, J., & Kerrigan, T. (2026). Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series. Headache: The Journal of Head and Face Pain, 66(8), 1916-1919. https://doi.org/10.1111/head.70152
Vancouver
Shah T, Dougherty C, Ailani J, Kerrigan T. Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series. Headache: The Journal of Head and Face Pain. 2026;66(8):1916-1919. doi:10.1111/head.70152
BibTeX
@article{Shah2026,
author = {Shah, Tulsi and Dougherty, Carrie and Ailani, Jessica and Kerrigan, Thomas},
title = {Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {8},
pages = {1916--1919},
doi = {10.1111/head.70152}
}
EUVIMED